The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Modulating metabolism to increase sensitivity to anti-myeloma drugs & targeting metabolites
Mala Shanmugam, MS, PhD , Emory School of Medicine, Atlanta, GA, comments on modulating metabolism to increase sensitivity to anti-myeloma therapies and discusses the importance of better understanding the role of metabolism in high-risk disease. Dr Shanmugam also highlights the challenges related to targeting metabolites to treat multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
